Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules (UH2/UH3)

The summary for the Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules (UH2/UH3) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules (UH2/UH3): The National Center for Advancing Translational Sciences (NCATS) seeks to expand the therapeutics discovery program piloted in 2012, to explore new therapeutic uses for proprietary drug candidates (Agents) across a broad range of human diseases. This innovative program allows investigators to propose new therapeutic uses for Agents from pharmaceutical company partners. A strong application will be supported by scientific evidence that modulation of the Agents target will have a positive impact on the disease/condition. PAR-14-213 encourages X02 pre-applications for the NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules.The X02 pre-application is the first step in the application process for PAR-14-212, PAR-14-210, PAR-14-211; applicants must read all of the companion FOAs.The X02 pre-applications will be evaluated by outside experts. Investigators whose X02 pre-applications are judged to be the most meritorious will be notified of the opportunity to submit a UH2/UH3 application under this FOA or PAR-14-212, or a UH3 application under PAR-14-211. The UH2/UH3 is a two stage application. 1. The UH2 (Stage 1) for this FOA may be used to support milestone-driven preclinical studies to perform juvenile toxicity testing and verify target engagement in a disease model and Phase 1a and 1b trials for a period that may vary from one to two years.UH2 projects that have met the scientific milestones and feasibility requirements will be eligible for rapid transition to the second UH3 stage after NIH administrative review. 2. The UH3 (Stage 2) will support milestone-driven Phase 2a trials to demonstrate that the Agent, made available for this program by the pharmaceutical partners, modulates the target and has the potential to yield the desired clinical outcome in the proposed disease population.The project period for the UH3 stage is up to two years.
Federal Grant Title: Limited Competition for NIH-Industry Program: Discovering Pediatric New Therapeutic Uses for Existing Molecules (UH2/UH3)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health Income Security and Social Services
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-14-210
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.103, 93.121, 93.173, 93.242, 93.273, 93.279, 93.350, 93.853, 93.865, 93.866
CFDA Descriptions: Food and Drug Administration_Research; Oral Diseases and Disorders Research; Research Related to Deafness and Communication Disorders; Mental Health Research Grants; Alcohol Research Programs; Drug Abuse and Addiction Research Programs; National Center for Advancing Translational Sciences; Extramural Research Programs in the Neurosciences and Neurological Disorders; Child Health and Human Development Extramural Research; Aging Research
Current Application Deadline: Jan 16, 2015
Original Application Deadline: Jan 16, 2015
Posted Date: May 12, 2014
Creation Date: May 12, 2014
Archive Date: Feb 16, 2015
Total Program Funding:
Maximum Federal Grant Award: none
Minimum Federal Grant Award: none
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Public housing authorities/Indian housing authorities
Private institutions of higher education
Special district governments
Public and State controlled institutions of higher education
County governments
City or township governments
State governments
Native American tribal governments (Federally recognized)
Native American tribal organizations (other than Federally recognized tribal governments)
Independent school districts
Small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)
For profit organizations other than small businesses
Additional Information on Eligibility
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement
Grant Announcement Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
More Grants from the National Institutes of Health
NIDCR Mentoring Network to Support a Diverse Dental, Oral and Craniofacial Research Workfo...
Graduate Research Training Initiative for Student Enhancement (G-RISE) (T32)
Physical Sciences-Oncology Network (PS-ON): Physical Sciences-Oncology Projects (PS-OP) (U...
Center without Walls for PET Ligand Development for Alzheimer's disease related dementias ...
Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) is not endorsed by, or affiliated with, any government agency. Copyright ©2018